Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
Published studies and trials of oral and biologic disease-modifying antirheumatic drugs for the treatment of Sjögren's syndrome have shown disappointing results. Improvements in trial design, including development of consortia for the conduct of national and international multicenter studies and use of standardized classification and outcome measures coupled with the emergence of newer biologic, immunomodulatory, and small molecule agents, hopefully will result in the addition of disease-modifying agents to the armamentarium.
Carsons
Steven E
SE
SUNY at Stony Brook School of Medicine, Stony Brook, NY, USA. Scarsons@winthrop.org
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D012107:Research Design; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D001688:Biological Products; D007155:Immunologic Factors